VA-USF study finds cotinine reduces the brain plaques associated with dementia

Tampa, FL (For immediate release) — Cotinine, a compound derived from tobacco, reduced plaques associated with dementia and prevented memory loss in a mouse model of Alzheimer’s disease, a study led by researchers at Bay Pines VA Healthcare System and the University of South Florida found.

The findings are reported online in the Journal of Alzheimer’s Disease in advance of print publication.

“We found a compound that protects neurons, prevents the progression of Alzheimer’s disease pathology, enhances memory and has been shown to be safe,” said Valentina Echeverria Moran, PhD, a scientist at Bay Pines VA Healthcare System and an assistant professor of Molecular Medicine at USF Health. “It looks like cotinine acts on several aspects of Alzheimer’s pathology in the mouse model. That, combined with the drug’s good safety profile in humans, makes it a very attractive potential therapy for Alzheimer’s disease.”

Valentina Echeverria Moran, PhD, study lead author

While the current drugs for Alzheimer’s may help delay the onset of symptoms, none halt or reverse the processes of Alzheimer’s disease. In addition, existing drugs may have undesirable side effects.

Some epidemiological studies showed that people who smoke tend to have lower incidences of Parkinson’s disease and Alzheimer’s disease. Studies have widely attributed this apparently beneficial effect to nicotine, which has been reported to improve memory and reduce Alzheimer’s-like plaques in mice. However, nicotine’s harmful cardiovascular effects and addictive properties make the compound a less than ideal drug candidate for neurodegenerative diseases.

The Bay Pines VA/USF team decided to look at the effects of cotinine, the major byproduct of nicotine metabolism, in Alzheimer’s disease mice.  Cotinine is nontoxic and longer lasting than nicotine. Furthermore, its safety has already been demonstrated in human trials evaluating cotinine’s potential to relieve tobacco withdrawal symptoms.

The researchers administered cotinine daily for five months to young adult (2-month-old) mice genetically altered to develop memory problems mimicking Alzheimer’s disease as they aged. At the end of the five-month study, the Alzheimer’s mice treated with cotinine performed better on tasks measuring their working memory and thinking skills than untreated Alzheimer’s control mice. Long-term cotinine treatment appeared to provide the Alzheimer’s mice complete protection from spatial memory impairment; their performance in this area of testing was identical to that of normal mice without dementia.

The brains of Alzheimer’s mice treated with cotinine showed a 26-percent reduction in deposits of amyloid plaques, which are a hallmark of Alzheimer’s disease. Cotinine also inhibited the accumulation of the amyloid peptide oligomers – a predecessor of senile plaques – in the brains of these mice.  Furthermore, the researchers discovered that cotinine stimulated the signaling factor Akt, which promotes the survival of neurons and enhances attention and memory.

Senile plaques likely had not yet formed or were just beginning to accumulate in the brains of the young adult mice when long-term cotinine treatment was started.  The researchers suggest that “cotinine may be useful in preventing cognitive deterioration when administered to individuals not yet exhibiting Alzheimer’s disease cognitive impairment or those with mild cognitive impairment at early stages of the disease.”

The Bay Pines VA team that worked with lead researcher Valentina Echeverria Moran, PhD (far right), included, from left to right, Sarah Burgess, Sagar Patel and Ross Zeitlin.

The researchers are seeking additional support for a pilot clinical trial to investigate cotinine’s effectiveness in preventing progression to Alzheimer’s dementia in patients with mild cognitive impairment, Echeverria said. 

The VA-USF team is also studying the potential of the tobacco-derived compound to relieve fear-induced anxiety and help blunt traumatic memories in mouse models of post-traumatic stress disorder.

Study co-authors included researchers from the University of Miami, the University of Manchester (UK), Boston College, and Saitama Medical Center and Saitama Medical University (Japan).  The study was supported in part by awards from the Florida Department of Health’s James and Esther King Biomedical Research Program, the Alzheimer’s Association, the Department of Veterans Affairs and USF.

Publication citation:
“Cotinine Reduces Amyloid-β Aggregation and Improves Memory in Alzheimer’s Disease Mice,” Valentina Echeverria, Ross Zeitlin, Sarah Burgess, Sagar Patel, Arghya Barman, Garima Thakur, Magorzota Mamcarz, Li Wang, David B. Sattelle, Daniel A. Kirschner, Takashi Mori, Roger M. LeBlanc, Rajeev Prabhakar and Gary W. Arendash, Journal of Alzheimer’s Disease, 24 (4) 2011.  DOI: 10.3233/JAD-2011-102136, IOS Press.

About USF Health
USF Health is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida’s colleges of Medicine, Nursing, Public Health and Pharmacy, the School of Biomedical Sciences and the School of Physical Therapy and Rehabilitation Sciences; and the USF Physician’s Group. Ranked 34th in federal research expenditures for public universities by the National Science Foundation, the University of South Florida is a high impact global research university.

About the VA Research and Development Program
For more than 65 years, the Veterans Affairs (VA) Research and Development program has been improving veterans’ lives through innovation and discovery. The VA Research program, unique in that it is the only research program focused wholly on conducting groundbreaking research to meet the full spectrum of veterans’ medical needs, benefits from being part of the Veterans Health Administration (VHA)—an integrated, national health care system with a state-of-the-art electronic health record. Through dynamic combination, the VA Research program is able to promote the quick translation of research findings into advancements in health care for veterans and all Americans.

About the Journal of Alzheimer’s Disease (JAD)
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer’s Disease has an Impact Factor of 3.82 according to Thomson Reuters’ 2010 edition of Journal Citation Reports. It is ranked #19 on the Index Copernicus Top 100 Journal List. The Journal is published by IOS Press.

Media contacts:
Bay Pines VA Healthcare System Public Affairs
Faith Belcher, (727) 398-9531 or faith.belcher2@va.gov

USF Health Public Affairs
Anne DeLotto Baier, (813) 974-3300 or abaier@health.usf.edu